Anika Therapeutics
ANIK
157 hedge funds and large institutions have $404M invested in Anika Therapeutics in 2019 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 76 increasing their positions, 34 reducing their positions, and 22 closing their positions.
124% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 34
4.02% more ownership
Funds ownership: 89.83% → 93.85% (+4%)
3% less funds holding
Funds holding: 162 → 157 (-5)
6% less capital invested
Capital invested by funds: $429M → $404M (-$25.2M)
14% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 22
43% less call options, than puts
Call options by funds: $6.65M | Put options by funds: $11.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$15M |
| 2 |
State Street
Boston,
Massachusetts
|
+$7.72M |
| 3 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
+$5.98M |
| 4 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$5.44M |
| 5 |
D.E. Shaw & Co
New York
|
+$5.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$13.8M |
| 2 |
EC
Engaged Capital
Newport Beach,
California
|
-$12.6M |
| 3 |
AAM
AMI Asset Management
Los Angeles,
California
|
-$10.8M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.5M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$3.56M |
ANIK Hedge Fund Activity: Q1 2019 in Review
157 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2019, worth a combined $404M — down 5.9% from $429M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ANIK and 19 opened new positions — a net loss of 3 holders — while 34 trimmed existing stakes and 76 added.
The largest buyer was Ameriprise, adding an estimated $15M. The largest seller was First Manhattan, exiting entirely with an estimated $13.8M sold.
- 157 institutional investors held Anika Therapeutics (ANIK) as of Q1 2019, down from 162 in Q4 2018.
- Funds reported $404M of Anika Therapeutics stock for Q1 2019, down 5.9% quarter-over-quarter.
- 19 funds opened new Anika Therapeutics positions in Q1 2019 and 22 closed out, a net change of -3 holders.
- The largest Anika Therapeutics buyer in Q1 2019 was Ameriprise, an estimated $15M added.
- The largest Anika Therapeutics seller in Q1 2019 was First Manhattan, an estimated $13.8M sold.
Based on aggregated 13F filings for Q1 2019.